The business case for cell and gene therapies

Nature Biotechnology

Volumn 32, Issue 12, 2014, Pages 1192-1193

  Abou El Enein, Mohamed ^a   Bauer, Gerhard ^b   Reinke, Petra ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DEAMINASE;

ADENOSINE DEAMINASE DEFICIENCY; CELL BASED GENE THERAPY; CELL THERAPY; COMMERCIAL PHENOMENA; DEVELOPING COUNTRY; DRUG INDUSTRY; DRUG MANUFACTURE; ENGRAFTMENT; FOLLOW UP; GENE THERAPY; GOOD MANUFACTURING PRACTICE; HEALTH CARE COST; HEALTH CARE QUALITY; HEALTH INSURANCE; HEMATOPOIETIC STEM CELL; HUMAN; LETTER; PRIORITY JOURNAL; REIMBURSEMENT; UNITED STATES; BIOLOGICAL THERAPY; COST BENEFIT ANALYSIS; ECONOMICS;

CELL- AND TISSUE-BASED THERAPY; COST-BENEFIT ANALYSIS; GENETIC THERAPY; HUMANS;

EID: 84922188493     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.3084     Document Type: Letter

References (9)

1. Ylä-Herttuala, S. Mol. Ther. 20, 1831-1832 (2012).
2. Xin, H. Science 314, 1233 (2006).
3. Brennan, T.A. & Wilson, J.M. Nat. Biotechnol. 32, 874-876 (2014).
4. Cook, J.P., Vernon, J.A. & Manning, R. Pharmacoeconomics 26, 551-556 (2008).
5. Neumann, P.J., Chambers, J.D., Simon, F. & Meckley, L.M. Health Aff. (Millwood) 30, 2329-2337 (2011).
6. Candotti, F. et al. Blood 120, 3635-3646 (2012).
7. Faulkner, E. et al. Value Health 15, 1162-1171 (2012).
8. Abou-El-Enein, M. et al. Cytotherapy 15, 362-383 (2013).
9. Abou-El-Enein, M., Bauer, G., Reinke, P., Renner, M. & Schneider, C.K. Trends Mol. Med. 20, 632-642 (2014).